<SEC-DOCUMENT>0001193125-22-001779.txt : 20220104
<SEC-HEADER>0001193125-22-001779.hdr.sgml : 20220104
<ACCEPTANCE-DATETIME>20220104164525
ACCESSION NUMBER:		0001193125-22-001779
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220104
DATE AS OF CHANGE:		20220104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261871
		FILM NUMBER:		22506857

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d278779d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>As Filed Pursuant to Rule 424(b)(3) <BR> Registration No. 333-261871<BR> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g278779g01a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>2,008,032 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock Offered by the Selling Stockholder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale from time to time of up to 2,008,032 shares of common stock, par value $0.001 per share, of X4
Pharmaceuticals, Inc. (the &#147;Common Stock&#148;) by the selling stockholder listed on page&nbsp;7 (the &#147;Selling Stockholder&#148;), including its pledgees, assignees, donees, transferees or their respective <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> which consists of 2,008,032 shares of our Common Stock issuable upon the exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our
Common Stock held by the Selling Stockholder. We will not receive any proceeds from the sale of the shares offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have agreed, pursuant to a registration rights agreement that we have entered into with the Selling Stockholder, to bear all of the expenses incurred in connection with the registration of these shares. The Selling Stockholder will pay or assume
discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of these shares of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholder identified in this prospectus, or its pledgees, assignees, donees, transferees or their respective <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> may offer the shares from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through any other means
described in this prospectus under the caption &#147;Plan of Distribution.&#148; The shares may be sold at fixed prices, at prevailing market prices, at prices related to prevailing market prices or at negotiated prices. For more information on the
Selling Stockholder, see the section entitled &#147;Selling Stockholder&#148; on page 7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may amend or supplement this prospectus from
time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is traded on the Nasdaq Capital Market under the symbol &#147;XFOR.&#148; On December&nbsp;31, 2021, the last reported sale
price of our Common Stock was $2.29 per share. You are urged to obtain current market quotations for our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company&#148; under applicable Securities and Exchange Commission rules and, as such, have elected to comply with certain reduced public company disclosure requirements for this prospectus and future filings. See &#147;Prospectus
Summary&#151;Implications of Being an Emerging Growth Company.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B><I>Investing
in our Common Stock involves a high degree of risk. You should carefully read and consider the section entitled &#147;<A HREF="#toc278779_5">Risk Factors</A>&#148; on page 5 and the risk factors included in our periodic reports filed with the
Securities and Exchange Commission (&#147;SEC&#148;), in any applicable prospectus supplement and in any other documents we file with the SEC. </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE
SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is January&nbsp;3, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_7">SELLING STOCKHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc278779_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the
heading&nbsp;&#147;Where You Can Find Additional Information,&#148;&nbsp;before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should
rely only on the information contained or incorporated by reference in this prospectus and the applicable prospectus supplement or in any amendment to this prospectus. Neither we nor the Selling Stockholder has authorized anyone to provide you with
different information, and if anyone provides, or has provided you,&nbsp;with different or inconsistent information, you should not rely on it. The Selling Stockholder is offering to sell, and seeking offers to buy, shares of our Common Stock only
in jurisdictions where offers and sales are permitted. The information contained in this prospectus, as well as the information filed previously with the SEC, and incorporated herein by reference, is accurate only as of the date of the document
containing the information, regardless of the time of delivery of this prospectus or any applicable prospectus supplement or any sale of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and
any applicable prospectus supplement together with additional information described below under the heading&nbsp;&#147;Where You Can Find Additional Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, references to&nbsp;&#147;X4 Pharmaceuticals,&#148; &#147;X4,&#148;&nbsp;the &#147;Company,&#148;&nbsp;the
&#147;registrant,&#148;&nbsp;&#147;we,&#148;&nbsp;&#147;us,&#148;&nbsp;and&nbsp;&#147;our&#148;&nbsp;refer to X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., and its subsidiaries. The phrase&nbsp;&#147;this prospectus&#148;&nbsp;refers to this
prospectus and any applicable prospectus supplement, unless the context requires otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any applicable prospectus supplement or free writing prospectus, including the documents incorporated by reference herein
and therein, contain forward-looking statements. These are based on our management&#146;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing
these forward-looking statements may be found, among other places, in the sections entitled &#147;Business,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
contained in the documents incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statements in this prospectus, or incorporated herein, about our
expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended (&#147;the Exchange Act&#148;), these forward-looking statements include statements regarding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our planned clinical trials for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical utility of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, operations,
strategy, goals and anticipated timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, develop and commercialize additional
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to identify additional product candidates with significant commercial potential that are consistent
with our commercial objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future revenue, expenses and needs for additional financing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors&#148; in our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and other filings we make with the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148;
&#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue,&#148;
&#147;likely,&#148; and similar expressions (including their use in the negative) intended to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are based on assumptions
and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading &#147;Risk Factors&#148; in our
SEC filings, and may provide additional information in any applicable prospectus supplement. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify all of the forward-looking statements in the foregoing documents by these
cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means
that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our Common Stock, you should carefully consider the risk factors incorporated by reference herein, in addition to the other
information set forth in this prospectus and in the documents incorporated by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights important features of this offering and the information included or incorporated by reference in this prospectus.
This summary does not contain all of the information you should consider before investing in our Common Stock. You should carefully read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this
prospectus and any applicable prospectus supplement before you invest in our Common Stock.</I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a late-stage clinical biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for
the treatment of rare diseases. Our pipeline is comprised of potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> oral, small molecule antagonists of chemokine receptor CXCR4, which have the
potential to treat a broad range of rare diseases, including primary immunodeficiencies and certain types of cancer. Our lead product candidate, mavorixafor, is a potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> oral, allosteric antagonist of the CXCR4 receptor designed to correct the abnormal signaling caused by the receptor/ligand interaction and enable
mobilization and trafficking of immune cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2019, we initiated 4WHIM, a pivotal,
<FONT STYLE="white-space:nowrap">52-week</FONT> global Phase 3 clinical trial of mavorixafor for the treatment of patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) Syndrome, a rare, inherited primary immunodeficiency
disease, following the completion of the dose-titration portion of a Phase 2 clinical trial whose open-label extension portion is ongoing. The U.S. Food and Drug Administration (&#147;FDA&#148;) has granted Breakthrough Therapy Designation for
mavorixafor for the treatment of adults with WHIM. The FDA has also granted Fast Track Designation for mavorixafor for adults with WHIM and Rare Pediatric Designation for mavorixafor for the treatment of WHIM. In November 2019, we initiated a <FONT
STYLE="white-space:nowrap">14-day,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 1b clinical trial of mavorixafor in patients with severe congenital neutropenia, and in December 2019,
we initiated a Phase 1b clinical trial of mavorixafor, in combination with ibrutinib, in patients with Waldenstr&ouml;m&#146;s macroglobulinemia, a rare blood cancer characterized by an excess of abnormal white blood cells in the bone marrow and
confirmed MYD88 and CXCR4 genetic mutations. We are also investigating mavorixafor in combination with axitinib (Inlyta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in the Phase 2a portion of an open-label Phase 1/2 clinical trial in
clear cell renal cell carcinoma. We intend to pursue future development and potential commercialization of mavorixafor in ccRCC and other possible immuno-oncology indications outside of greater China only as part of a potential strategic
collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also advancing two early stage candidates: <FONT STYLE="white-space:nowrap">X4P-003,</FONT> a second-generation
CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling broader opportunities in CXCR4-dependent disorders and primary immunodeficiencies; and <FONT STYLE="white-space:nowrap">X4P-002,</FONT> a CXCR4
antagonist with a unique distribution profile for potential use in CXCR4-dependent diseases in the periphery, but also with the ability to cross the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers and other
diseases where exposure in brain is essential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated revenue from product sales and do not expect to generate
significant revenue from the sale of our products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot
predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Securities Purchase Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;5, 2021, we entered into a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) with BCLS II Investco, LP (the &#147;Purchaser&#148;), an affiliate of Bain Capital Life Sciences, LLC, pursuant to which we agreed to sell
and issue <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase an aggregate of 2,008,032 shares of Common Stock at a price of $0.01 per share, at a purchase price of $4.97 per <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant (the &#147;Private Placement&#148;). On November&nbsp;9, 2021, we closed the Private Placement and issued 2,008,032 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Common Stock to the Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original issuance and will not expire.
The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants provide that the holder of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will not have the right to exercise any portion of its
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to such
exercise (the &#147;Beneficial Ownership Limitation&#148;); provided, however, that the holder may increase or decrease the Beneficial Ownership Limitation by giving 61 days&#146; notice to us, but not to any percentage in excess of 19.99%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants were not initially
registered under the&nbsp;Securities Act&nbsp;or any state securities laws. We have relied on the exemption from the registration requirements of the&nbsp;Securities Act&nbsp;by virtue of Section&nbsp;4(a)(2) thereof. In connection with its
execution of the Purchase Agreement, the Purchaser represented to us that the Purchaser is an &#147;accredited investor&#148; as defined in&nbsp;Regulation D&nbsp;of the&nbsp;Securities Act&nbsp;and that the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by the Purchaser were being acquired solely for its own account and for investment purposes and not with a view to its future sale or distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;5, 2021, in connection with the Private Placement, we entered into a Registration Rights Agreement with the Purchaser (the &#147;Registration Rights Agreement&#148;), pursuant to which we agreed to (i)&nbsp;by no later than
December&nbsp;31, 2021, file a registration statement with the SEC to cover the resale of the shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Common Stock issued to the
Purchaser pursuant to the Purchase Agreement (the &#147;Shares&#148;), (ii) to use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable and (iii)&nbsp;to keep such registration statement
effective until the date the Shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction. In the event that such registration statement is not filed or declared effective within the
timeframes set forth in the Registration Rights Agreement or, after the registration statement has been declared effective by the SEC, sales cannot be made pursuant to the registration statement for any reason including by reason of a stop order or
our failure to update such registration statement, subject to certain limited exceptions, then we have agreed to make payments to the Purchaser as liquidated damages in an amount equal to 1% of the aggregate amount invested by the Investor in the
Shares per <FONT STYLE="white-space:nowrap">30-day</FONT> period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the registration rights agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus is a part relates to the offer and resale of the Shares issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Common Stock issued to the Purchaser pursuant to the Purchase Agreement. When we refer to the Selling Stockholder in this prospectus, we are referring to the Purchaser named in this
prospectus as the Selling Stockholder and, as applicable, any donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling Shares received after the
date of this prospectus from the Selling Stockholder as a gift, pledge, or other <FONT STYLE="white-space:nowrap">non-sale</FONT> related transfer. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to March&nbsp;13, 2019, we were a clinical-stage biopharmaceutical company known as Arsanis, Inc. that had historically been focused on
applying monoclonal antibody immunotherapies to address serious infectious diseases. Arsanis, Inc. was originally incorporated in the State of Delaware in August 2010. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;13, 2019, we completed our business combination with X4 Therapeutics, Inc. (formerly X4&nbsp;Pharmaceuticals, Inc.) in
accordance with the terms of an Agreement and Plan of Merger, dated as of November&nbsp;26, 2018, as amended on December&nbsp;20, 2018 and March&nbsp;8, 2019 (the &#147;Merger Agreement&#148;), that we entered into with X4 Therapeutics, Inc. and
Artemis AC Corp., a Delaware corporation and our wholly owned subsidiary (&#147;Merger Sub&#148;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into X4 Therapeutics, Inc., with X4 Therapeutics, Inc. continuing as our
wholly owned subsidiary and the surviving corporation of the merger, which transaction we refer to as the Merger. At the closing of the Merger, we issued shares of our Common Stock to X4 Therapeutics, Inc. stockholders based on an agreed upon
exchange ratio, and each option or warrant to purchase X4 Therapeutics, Inc. capital stock became an option or warrant, respectively, to purchase our Common Stock, subject to adjustment in accordance with the agreed upon exchange ratio. Following
the closing of the Merger, we effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-6</FONT></FONT> reverse stock split of our Common Stock, our name was changed to X4 Pharmaceuticals, Inc., the business of X4
Therapeutics, Inc. became our business, and we became a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. In connection with the closing of
the Merger, our stock began trading on the Nasdaq Capital Market under the symbol &#147;XFOR&#148; on March&nbsp;14, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal
executive offices are located at 61 North Beacon Street, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, Massachusetts 02134, and our telephone number is (857) <FONT STYLE="white-space:nowrap">529-8300.</FONT> Our website is
located at http://www.x4pharma.com. We do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Offered by the Selling Stockholder </P></TD>
<TD>2,008,032 Shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the Shares covered by this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market Symbol </P></TD>
<TD>XFOR </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_5"></A>RISK&nbsp;FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our Common Stock involves a high degree of risk. Prior to making a decision about investing in our Common Stock, you should
consider carefully the specific risk factors discussed in the sections entitled&nbsp;&#147;Risk Factors&#148;&nbsp;contained in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
September&nbsp;30, 2021, as filed with the SEC on November&nbsp;4, 2021, which are incorporated in this prospectus by reference in their entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC,
including any prospectus supplement hereto. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our
business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected.
In that case, the trading price of our Common Stock could decline and you might lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are filing the registration statement of which this prospectus forms a part to permit the holder of the Shares of our Common Stock
described in the section entitled &#147;Selling Stockholder&#148; to resell such Shares. We are not selling any securities under this prospectus, and we will not receive any proceeds from the sale or other disposition of shares of our Common Stock
held by the Selling Stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholder will pay any underwriting discounts and commissions and expenses incurred by the
Selling Stockholder for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholder in disposing of these Shares. We will bear all other costs, fees and expenses incurred in effecting the registration of
the Shares covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_7"></A>SELLING STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus covers the sale or other disposition by the Selling Stockholder of up to the total number of shares of our Common Stock
issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued to the Selling Stockholder, without giving effect to the Beneficial Ownership Limitation described under &#147;Prospectus Summary&#151;Private
Placement&#151;Securities Purchase Agreement.&#148; The table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of our Common Stock by the Selling Stockholder as of December&nbsp;20, 2021. The information
in the table below with respect to the Selling Stockholder has been obtained from the Selling Stockholder. When we refer to the &#147;Selling Stockholder&#148; in this prospectus, or, if required, a post-effective amendment to the registration
statement of which this prospectus is a part, we mean the Selling Stockholder listed in the table below as offering shares, as well as its respective pledgees, assignees, donees, transferees or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest.</FONT></FONT> Throughout this prospectus, when we refer to the shares of our Common Stock being registered on behalf of the Selling Stockholder, we are referring to the shares underlying the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants issued to the Selling Stockholder pursuant to the Purchase Agreement, without giving effect to the Beneficial Ownership Limitation described above. The Selling Stockholder may sell all, some or
none of the shares of Common Stock subject to this prospectus. See &#147;Plan of Distribution&#148; below as it may be supplemented and amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock beneficially owned prior to the offering for the Selling Stockholder includes all shares of our Common
Stock beneficially held by the Selling Stockholder as of December&nbsp;20, 2021, which includes all shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by the Selling Stockholder
in the Private Placement, without giving effect to the Beneficial Ownership Limitation. The percentages of shares owned before and after the offering are based on 28,127,315 shares of Common Stock outstanding as of December&nbsp;20, 2021, which does
not include any shares of Common Stock offered by this prospectus that are issuable pursuant to warrants or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and are deemed outstanding in the table below because they are beneficially owned
by the Selling Stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment
power with respect to our Common Stock. Generally, a person &#147;beneficially owns&#148; shares of our Common Stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to
acquire voting or disposition rights within 60 days. In computing the number of shares of our Common Stock beneficially owned by the Selling Stockholder and the percentage ownership of the Selling Stockholder, we deemed outstanding shares of Common
Stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or warrants held by the Selling Stockholder that are exercisable within 60 days of December&nbsp;20, 2021. The inclusion of any shares in this table does
not constitute an admission of beneficial ownership for the Selling Stockholder named below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Common Stock<BR>Beneficially Owned<BR>Prior&nbsp;to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common&nbsp;Stock<BR>Being&nbsp;Offered(1)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Common Stock<BR>to be Beneficially<BR>Owned After<BR>Offering(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Selling Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCLS II Investco, LP (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,008,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,008,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of our Common Stock in the column &#147;Number of Shares of Common Stock Being
Offered&#148; represents all of the shares of our Common Stock that the Selling Stockholder may offer and sell from time to time under this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts the Selling Stockholder may offer shares for sale. The Selling
Stockholder might not sell any or might sell all of the shares offered by this prospectus. Because the Selling Stockholder may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements or
understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the Selling Stockholder after completion of the offering. However, for
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
purposes of this table, we have assumed that, after completion of the offering, none of the shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued
in the Private Placement and covered by this prospectus will be held by the Selling Stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consists
of shares of Common Stock issuable upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by the Selling Stockholder in the Private Placement. Bain Capital Life Sciences Investors, LLC (&#147;BCLSI&#148;) is the
ultimate general partner of the Selling Stockholder. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the shares of Common Stock beneficially owned by the Selling Stockholder. Additionally, the shares of Common
Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants held by the Selling Stockholder are required to be aggregated with our other securities beneficially owned by BCLSI and other affiliates of the Selling
Stockholder for the purposes of the Beneficial Ownership Limitation contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. The address of the Selling Stockholder is c/o Bain Capital Life Sciences, LP, 200 Clarendon Street,
Boston, MA 02116. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationships with Selling Stockholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in greater detail above under the section titled&nbsp;&#147;<I>Prospectus Summary&#151;Private Placement</I>&#148;&nbsp;in
November 2021, we entered into the Purchase Agreement with the Selling Stockholder, pursuant to which we sold and issued <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase our Common Stock, and we also entered into the
Registration Rights Agreement with the Selling Stockholder, pursuant to which we agreed to file a registration statement with the SEC to cover the resale by the Selling Stockholder of the shares of Common stock issuable upon exercise by the Selling
Stockholder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued pursuant to the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling
Stockholder has not had a material relationship with us or any of our predecessors or affiliates within the past three years, other than as a result of the ownership of our shares of Common Stock or other securities, and the Selling Stockholder has
not held any position or office with us or our affiliates within the last three years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholder, which as used herein includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of Common Stock or interests in shares of Common Stock received after the date of this prospectus from the Selling Stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of Common Stock or interests in shares of Common Stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholder may use any one or more of the following methods when disposing of shares or interests therein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales effected after the date the registration statement of which this prospectus is a part is declared
effective by the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the Selling Stockholder to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholder may, from time to time, pledge or grant a security interest in some or all of the shares of Common Stock owned by the
Selling Stockholder and, if the Selling Stockholder defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock, from time to time, under this prospectus, or under an
amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), amending the selling stockholder list to include the pledgee, transferee or other successors
in interest as selling stockholders under this prospectus. The Selling Stockholder also may transfer the shares of Common Stock in other circumstances, in which case the transferees, pledgees, donees or other successors in interest will be the
selling beneficial owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our Common Stock or interests therein, the
Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Common Stock in the course of hedging the positions they assume. The Selling Stockholder may
also sell shares of our Common Stock short and deliver these securities to close out their short positions, or loan or pledge the Common Stock to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into
option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this
prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the Selling Stockholder from the sale of the Common Stock offered
by the Selling Stockholder will be the purchase price of the Common Stock less discounts or commissions, if any. The Selling Stockholder reserves the right to accept and, together with its agents from time to time, to reject, in whole or in part,
any proposed purchase of Common Stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants by payment of cash,
however, we will receive the exercise price of $0.01 per share pursuant to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholder also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the
Securities Act of 1933, provided that the Selling Stockholder meets the criteria and conform to the requirements of that rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Selling Stockholder and any underwriters, broker-dealers or agents that participate in the sale of the Common Stock or interests therein may be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act. Any discounts,
commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. A Selling Stockholder who is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(11) of the
Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of our
Common Stock to be sold, the name of the Selling Stockholder, the respective purchase price and public offering price, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer
will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the Common Stock may be sold in these jurisdictions only through
registered or licensed brokers or dealers. In addition, in some states the Common Stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied
with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Stockholder that the anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934,
as amended, may apply to sales of shares in the market and to the activities of the Selling Stockholder and its affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time
to time) available to the Selling Stockholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholder may indemnify any broker-dealer that participates in transactions involving the sale of
the shares against certain liabilities, including liabilities arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the Selling
Stockholder against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the Selling Stockholder to use commercially reasonable efforts to cause the registration statement of which this
prospectus constitutes a part effective and to remain continuously effective until the earlier of (1)&nbsp;such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement
or (2)&nbsp;the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the Shares to be offered for resale by the Selling Stockholder under this prospectus will be passed upon for us by Cooley LLP,
New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference to the Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to our ability to continue as a going concern as described
in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC. This prospectus omits some information contained in the
registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and our securities. Statements in
this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete
document to evaluate these statements. You can obtain a copy of the registration statement from the SEC&#146;s website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual,
quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available, free of charge, through our investor relations website, our Annual Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> statements of changes in beneficial ownership of
securities and amendments to those reports and statements as soon as reasonably practicable after they are filed with the SEC. The address for our website is www.x4pharma.com. Information contained in or accessible through our website does not
constitute a part of this prospectus and is not incorporated by reference in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc278779_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-38295.</FONT> The documents
incorporated by reference into this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are
incorporated by reference into this document: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828021005202/xfor-20201231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2020 (the &#147;2020 Annual Report&#148;), filed with the SEC on March&nbsp;19, 2021, including the information specifically incorporated by reference in
the 2020 Annual Report from our <A HREF="http://www.sec.gov/Archives/edgar/data/1501697/000162828021007220/a2021def14a.htm">definitive proxy statement</A> for the 2021 Annual Meeting of Stockholders, filed with the SEC on April&nbsp;20, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended
March&nbsp;31, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828021009166/xfor-20210331.htm">May<U></U>&nbsp;6, 2021</A>, our Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended June&nbsp;
30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828021015330/xfor-20210630.htm">August<U></U>&nbsp;3, 2021</A>, and our Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended September&nbsp;
30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828021021795/xfor-20210930.htm">November<U></U>&nbsp;4, 2021</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021005139/xfor-20210318.htm">March
<U></U>&nbsp;19, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021011738/xfor-20210607.htm">June<U></U>&nbsp;
7, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021012055/xfor-20210611.htm">June<U></U>&nbsp;
11, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021013883/xfor-20210715.htm">July<U></U>&nbsp;
15, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021014331/xfor-20210720.htm">July<U></U>&nbsp;
23, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021018381/xfor-20210910.htm">September<U></U>&nbsp;
10, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021020237/xfor-20211014.htm">October<U></U>&nbsp;
19, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021022069/xfor-20211105.htm">November<U></U>&nbsp;
5, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021023141/xfor-20211111.htm">November<U></U>&nbsp;
12, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021023371/xfor-20211115.htm">November<U></U>&nbsp;
15, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001501697/000162828021024958/xfor-20211213.htm">December<U></U>&nbsp;13, 2021</A> (in each case, except for information contained therein which is
furnished rather than filed); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our Common Stock set forth in the registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517343308/d450669d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> registering our Common Stock under Section&nbsp;12 of the Exchange Act, which was filed with the SEC on November&nbsp;15, 2017, including any amendments or reports filed for purposes of updating such
description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1501697/000162828021005202/descriptionofcommonstock.htm">Exhibit 4.12</A> to the 2020 Annual Report. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial
filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as
well as proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without
charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such
documents. You should direct any requests for documents to X4 Pharmaceuticals,&nbsp;Inc., Attn: Investor Relations, 61 North Beacon Street, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, Massachusetts 02134. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this
prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be incorporated by reference into this prospectus,
modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>2,008,032 Shares </B></P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g278779g01a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:37%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:37%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;3, 2022 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g278779g01a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g278779g01a03.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !' '(# 1$  A$! Q$!_\0
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M#>*,EJAF?\I0:'/86BJ;>*0WJY3.B3XAXRG5SG&47RN57/5?'P, #VP ,?\
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MYON'R.A+G;=LE/F'1LI<OJ"KMD?5#4RT,>/2\IFD]:^"PK'\G&A/J\+Z7W7
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MRI5,VW#,E=3I&S1GV6M'241M77PK41(,@LGO)*Y '(3G,B-C'$^&,&,JL?\
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M$DO)@ "7F;ED@8!+-D# UUH$I4TBI5DJU8XUXPU(%B@1%)+8B@C"JJDECA$
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M:YBZG49*^785RLL;$]58RZ<LNJDS(GH8U>237F.,+C1G.VH8K\$P>O'<AGC
M8/"DT<R!PRA@R .H<<@"" PY#N,ZT[)VVY7:"V:-JK,2KPV?+SUY3&RL5:.7
ME&Y1N#$$'BW$X!P=<!>+>IB0ELEXYZ[)7-LOPSIZY#C7[)MO]NDO\4LK\?\
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7E:&]S_.?[=7N3Z%_T5_L&LOF->M?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
